ENERGY STORAGE OEM A Q U E O U S B A T T E R Y G A S K E T • Sealing performance from -40 to 110°F • Ability to flow in a long, thin seal design • Chemical resistance to a proprietary electrolyte solution • Natural color • Provided a chemically resistant TPE that outperformed competitive TPE and thermoplastic rubber in rigorous customer testing • Offered material expertise and education to empower an informed material decision • Enabled OEM to model and evaluate sealing performance via design support and data files • Met global production needs through material consistency and local technical support Dynaflex™ Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT?

Reconciliation to condensed consolidated statements of income Three months ended March 31, 2025 2024 $ Millions EPS (in $) $ Millions EPS (in $) Net (loss) income attributable to Avient common shareholders (20.2) (0.22) 49.4 0.54 Special items, after-tax 75.7 0.82 5.5 0.06 Amortization expense, after-tax 14.5 0.16 14.9 0.16 Adjusted net income / EPS 70.0 0.76 69.8 0.76 Per share amounts may not recalculate from figures present herein due to rounding 11 1 Reconciliation to EBITDA and Adjusted EBITDA Three months ended March 31, 2025 2024 $ Millions $ Millions Net (loss) income – GAAP (19.9) 49.7 Income tax (benefit) expense (6.7) 16.8 Interest expense, net 26.9 26.6 Depreciation & amortization 45.3 44.3 EBITDA 45.6 137.4 Special items, before tax 101.2 6.2 Interest expense included in special items (1.7) - Depreciation & amortization included in special items (0.4) (0.5) Adjusted EBITDA 144.7 143.1 Adjusted EBITDA as a percent of sales 17.5% 17.3% PAGE 1 OF 3 Copyright © . All Rights Reserved 2025 30 Reconciliation of Non-GAAP financial measures Reconciliation to EBITDA and Adjusted EBITDA Three months ended March 31, 2025 2024 $ Millions $ Millions Sales Color, Additives and Inks 519.7 515.3 Specialty Engineered Materials 308.4 314.4 Corporate (1.5) (0.7) Sales 826.6 829.0 Operating income Color, Additives and Inks 78.6 74.8 Specialty Engineered Materials 47.1 53.4 Corporate (125.0) (34.2) Operating income 0.7 94.0 Depreciation and amortization Color, Additives and Inks 21.7 21.9 Specialty Engineered Materials 21.5 19.6 Corporate 2.1 2.8 Depreciation and amortization 45.3 44.3 EBITDA Earnings before interest, taxes, depreciation and amortization Color, Additives and Inks 100.3 96.7 Specialty Engineered Materials 68.6 73.0 Corporate (122.9) (31.4) Other expense, net (0.4) (0.9) EBITDA 45.6 137.4 Special items, before tax 101.2 6.2 Interest expense included in special items (1.7) - Depreciation and amortization included in special items (0.4) (0.5) Adjusted EBITDA 144.7 143.1 Adjusted EBITDA as a percent of sales Color, Additives and Inks 19.3% 18.8% Specialty Engineered Materials 22.2% 23.2% PAGE 2 OF 3 Copyright © . All Rights Reserved 2025 31 Reconciliation of Non-GAAP financial measures Reconciliation to condensed consolidated statements of income Three months ended March 31, 2023 $ Millions EPS (in $) Net income from continuing operations attributable to Avient common shareholders 20.8 0.23 Special items, after-tax 22.3 0.24 Amortization expense, after-tax 15.1 0.16 Adjusted net income / EPS 58.2 0.63 1 Reconciliation to EBITDA and Adjusted EBITDA Year ended December 31, 2024 $ Millions Net income – GAAP 170.7 Income tax expense 54.1 Interest expense 105.6 Depreciation & amortization 179.7 EBITDA 510.1 Special items, before tax 20.1 Interest expense included in special items (2.3) Depreciation & amortization included in special items (1.5) Adjusted EBITDA 526.4 Adjusted EBITDA as a percent of sales 16.2% PAGE 3 OF 3 Reconciliation to condensed consolidated statements of income Three months ended June 30, 2024 $ Millions EPS (in $) Net income attributable to Avient common shareholders 33.6 0.36 Special items, after-tax 21.8 0.24 Amortization expense, after-tax 14.8 0.16 Adjusted net income / EPS 70.2 0.76 Reconciliation to condensed consolidated statements of income Year ended December 31, 2024 $ Millions EPS (in $) Net (loss) income attributable to Avient common shareholders 169.5 1.84 Special items, after-tax 15.9 0.17 Amortization expense, after-tax 59.5 0.65 Adjusted net income / EPS 244.9 2.66 Per share amounts may not recalculate from figures present herein due to rounding 1 1 1 Q4 2024 Earnings webcast Slide 1 Slide 2: Disclaimer Slide 3: Avient at a glance...

Er personliga information hanteras och skyddas i enlighet med detta meddelande när ni skickar er ansökan, meritförteckning och/eller CV med hjälp av vårt online- ansökningsverktyg. Att skicka sådana uppgifter är dock frivilligt och ni är inte skyldiga att skicka dem som en del av er online-meritförteckning och -ansökan. Avient kan samla in er personliga information på följande sätt när ni gör en ansökan: • Online: När ni ansöker online med hjälp av webbplatserna; • Via e-post.

To access Avient’s news library online, please visit www.avient.com/news.

Taxes, Fees, and Duties. Such tax and duties will be added by Seller to the sales price when Seller has the legal obligation to collect the same and Buyer will pay such taxes and duties unless Buyer provides Seller with a proper tax exemption certificate for each jurisdiction in which taxes otherwise would be due. In the event Seller is required to pay any such tax or duty at the time of sale or thereafter, Buyer will promptly reimburse Seller for the total amount of any such tax or duties.

KEY CHARACTERISTICS • Globally harmonized formulations are manufactured at four ISO 13485 certified medical sites, providing global consistency and increased security of supply • Documented change control available • A range of standard colors eliminates color matching to expedite development time • The portfolio includes compliant colors for use in: - Needle hub applications: ISO 6009 - Ophthalmic container closures (American Academy of Ophthalmology) REGULATORY SUPPORT • A library of pre-tested raw materials including: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* HEALTHCARE APPLICATIONS • Medical devices such as catheters, surgical and dental instruments, and drug delivery devices • Pharmaceutical packaging including vials and bottles • Diagnostics for blood analysis or In Vitro Diagnostics (IVD) PRODUCT BULLETIN & COLOR CARD * FDA/EU compliance information available upon request; exceptions may occur Color Pantone Reference PE Base PP Base Transparent PP Base PEBA Base PC Base Transparent PC Base* ABS Base* White — PE0M176031 PP0M176045 ** AH0M415001 NC0M176058 ** SB0M665206 Yellow 102C PE1M176076 PP1M176060 PP1M176062 AH1M415002 NC1M176058 NC1M176059 SB1M664958 Orange 158C PE2M176044 PP2M176046 ** ** NC2M176044 NC2M664912 SB2M664939 Red 199C PE3M176131 PP3M176111 PP3M176113 AH3M415002 NC3M176116 NC3M176122 SB3M665037 Pink 196C PE3M176130 PP3M176109 ** AH3M415001 NC3M176117 NC3M665052 SB3M665039 Violet 2593C PE4M176023 PP4M176036 PP4M176039 AH4M415001 NC4M176038 NC4M176044 SB4M664978 Light Blue 292C PE5M176155 PP5M176169 ** AH5M415003 NC5M176142 ** SB5M665402 Mid Blue 285C PE5M176154 PP5M176171 PP5M176175 AH5M415002 NC5M176143 NC5M176146 SB5M665404 Dark Blue 288C PE5M176153 PP5M176173 ** ** NC5M176144 ** SB5M665406 Light Green 346C PE6M176128 PP6M176111 ** ** NC6M176118 ** SB6M665070 Bluish Green 3145C PE6M176126 PP6M176115 ** ** NC6M176119 ** SB6M665068 Medium Green 348C PE6M176127 PP6M176113 PP6M176118 AH6M415001 NC6M176120 NC6M176121 SB6M665072 Dark Gray 425C PE7M176066 PP7M176091 PP7M176094 ** NC7M176124 ** SB7M665297 Mid Gray Cool Gray 5C PE7M176067 PP7M176089 ** AH7M415001 NC7M176125 NC7M665175 SB7M665295 Beige 7502C PE8M176048 PP8M176058 ** ** NC8M176058 ** SB8M664871 Brown 463C/731C PE8M176049 PP8M176060 ** ** NC8M176059 ** SB8M664869 Black Black C PL9M176008 PP9M176017 ** ** NC9M176008 NC9M176009 SB9M664896 Colors may vary from actual color shown.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Available as pre-colored formulation or concentrate and for use in different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU** APPLICATION BULLETIN * Design note: Effect colors require careful consideration of part design and polymer flow paths to minimize visible flow lines.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number reducing risk of change • Non-phthalate and formulated without animal- derived substances • Available for use in a wide range of polymers including polyolefins, styrenics, polycarbonate and alloys, polyester, POM • Functionality can be combined with colorants into convenient combination concentrates and ready-to-use formulations REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request FUNCTIONALITY TARGET APPLICATIONS DRUG DELIVERY DEVICES SYRINGES & NEEDLES DIAGNOSTICS CATHETERS Clarifying PP Sorbitol-free for transparent applications with reduced migration and improved thermal stability     Lubricant— permanent/ non-migrating Fast acting reduction in friction for wide variety of polymers such as PP, ABS, POM, PC    Protection from UV in transparent applications for PP, PE, PETG, COP UV blocking in 290-450nm with no impact on clarity; can be combined with colors (e.g., amber)   Antistatic ready-to- use solution for PP, ABS, PC/ABS Permanent/non-migrating; fast decay time independent of % relative humidity  Gamma/e-beam sterilization protection of the polymer Preserving the properties of PP and COC/COP; reduction in yellowing using Color Compensation Technology (CCT)    Reduced material consumption/cycle time—nucleation Fast acting new generation nucleant for PE and PP; improved thermal and mechanical properties allows wall thinning; reduction of tolerance/dimensional problems between different colors    Laser marking replacing ink printing/labels Solvent-free, high-speed identification for Nd/YAG laser for PE,PP, ABS, PC, POM     Antioxidants for PE, PP, TPE Thermal protection during converting/downstream sterilization    Brand protection/ anticounterfeit Covert and non-covert systems   Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Designed for Nd:YAG lasers operating between 1060-1070 nm • Available for different polymers including PP, PE, PC, PBT, POM, ABS, MABS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Can be designed for dark marking on natural or white/light colored background or light marking on black/dark background REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request.

Avient does not provide reconciliations of forward-looking non-GAAP financial measures, such as outlook for Adjusted EBITDA, Adjusted Earnings Per Share and Adjusted Tax Rate, to the most comparable GAAP financial measures on a forward- looking basis because Avient is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. We also monitor earnings (defined as net income from continuing operations) before interest, taxes, depreciation and amortization (EBITDA) and adjusted EBITDA (EBITDA before the impact of special items) as a supplement to our GAAP measures. Three Months Ended December 31, 2023 2022 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net income (loss) from continuing operations attributable to Avient shareholders $ 27.8 $ 0.30 $ (17.0) $ (0.19) Special items, after tax (Attachment 3) 5.4 0.06 38.3 0.42 Amortization expense, after-tax 15.0 0.16 14.6 0.16 Adjusted net income / EPS $ 48.2 $ 0.52 $ 35.9 $ 0.39 (1) Per share amounts may not recalculate from figures presented herein due to rounding Year Ended December 31, 2023 2022 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net income from continuing operations attributable to Avient shareholders $ 75.8 $ 0.83 $ 82.8 $ 0.90 Special items, after tax (Attachment 3) 79.3 0.86 116.2 1.26 Amortization expense, after-tax 61.5 0.67 49.0 0.53 Adjusted net income / EPS $ 216.6 $ 2.36 $ 248.0 $ 2.69 (1) Per share amounts may not recalculate from figures presented herein due to rounding 1 Three Months Ended December 31, Year Ended December 31, Reconciliation to EBITDA and Pro Forma Adjusted EBITDA 2023 2022 2023 2022 Sales - GAAP $ 719.0 $ 790.4 $ 3,142.8 $ 3,396.9 Pro forma APM adjustments — — — 256.1 Pro forma adjusted sales $ 719.0 $ 790.4 $ 3,142.8 $ 3,653.0 Net income (loss) from continuing operations – GAAP $ 27.6 $ (16.6) $ 76.3 $ 83.1 Income tax (benefit) expense (7.0) (60.8) 11.0 (19.3) Interest expense 26.8 49.4 115.3 119.8 Depreciation and amortization from continuing operations 44.2 48.6 188.8 162.5 EBITDA from continuing operations $ 91.6 $ 20.6 $ 391.4 $ 346.1 Special items, before tax 22.4 104.3 114.6 194.0 Interest expense included in special items (0.1) (16.0) (2.3) (26.0) Depreciation and amortization included in special items — (1.5) (1.9) (5.5) Adjusted EBITDA $ 113.9 $ 107.4 $ 501.8 $ 508.6 APM pro forma adjustments - 8 months 2022* — — — 83.1 Pro forma adjusted EBITDA $ 113.9 $ 107.4 $ 501.8 $ 591.7 Pro forma adjusted EBITDA as a percent of sales 15.8 % 13.6 % 16.0 % 16.2 % * Pro forma adjustment for January - August 2022 APM results (period before Avient ownership).